The role of treatment of hepatitis C with direct-acting antiviral agents on glycaemic control in diabetic patients: An updated systematic review and meta-analysis.
direct acting antiviral agents
glycemic control
hepatitis c
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
revised:
25
05
2024
received:
06
11
2023
accepted:
16
07
2024
medline:
24
7
2024
pubmed:
24
7
2024
entrez:
24
7
2024
Statut:
aheadofprint
Résumé
Recent studies suggested that successful clearance of chronic Hepatitis C Virus (HCV) by using direct-acting antiviral (DAA) agents could improve glycemic control in patients with diabetes; however, some studies failed to identify this benefit. We conducted a systematic review and meta-analysis to assess the impact of sustained virologic response (SVR) after treatment with DAA agents on glycemic control. Embase, Scopus and PubMed were searched through March 26th, 2023, for all studies evaluating whether eradication of HCV infection with DAAs is associated with an impact on glycemic control. Only studies with data on glycemic control, including haemoglobin A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016. Hepatol Baltim Md. 2019;69(3):1020‐1031. doi:10.1002/hep.30297
Wang C‐C, Cheng P‐N, Kao J‐H. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 2020;51(2):216‐230. doi:10.1111/apt.15575
Jármay K, Karácsony G, Nagy A, Schaff Z. Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol: WJG. 2005;11(41):6422‐6428. doi:10.3748/wjg.v11.i41.6422
Ding Y, Li G, Zhou Z, Deng T. Molecular mechanisms underlying hepatitis C virus infection‐related diabetes. Metab Clin Exp. 2021;121:121. doi:10.1016/j.metabol.2021.154802
Benhammou JN, Moon AM, Pisegna JR, et al. Nonalcoholic fatty liver disease risk factors affect liver‐related outcomes after direct‐acting antiviral treatment for hepatitis C. Dig Dis Sci. 2021;66(7):2394‐2406. doi:10.1007/s10620-020-06457-2
Chehadeh W, Abdella N, Ben‐Nakhi A, Al‐Arouj M, Al‐Nakib W. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol. 2009;24(1):42‐48. doi:10.1111/j.1440-1746.2008.05503.x
Greenberg PD, Rosman AS, Eldeiry LS, Naqvi Z, Bräu N. Decline in haemoglobin A1c values in diabetic patients receiving interferon‐alpha and ribavirin for chronic hepatitis C. J Viral Hepat. 2006;13(9):613‐617. doi:10.1111/j.1365-2893.2006.00729.x
Unnikrishnan R, Anjana RM, Mohan V. Drugs affecting HbA1c levels. Indian J Endocrinol Metab. 2012;16(4):528‐531. doi:10.4103/2230-8210.98004
Falade‐Nwulia O, Suarez‐Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct‐acting agent therapy for hepatitis C virus infection. Ann Intern Med. 2017;166(9):637‐648. doi:10.7326/M16-2575
Mada PK, Malus ME, Parvathaneni A, et al. Impact of treatment with direct acting antiviral drugs on glycemic control in patients with hepatitis C and diabetes mellitus. Int J Hepatol. 2020;2020:6438753. doi:10.1155/2020/6438753
Abdo M, Rabiee A, Abdellatif Z, Abdel Alem S, Moustafa A. Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir. Eur J Gastroenterol Hepatol. 2021;33(12):1588‐1594. doi:10.1097/MEG.0000000000001903
Carnovale C, Gentili M, Magni C, et al. The impact of a successful treatment of HCV on glyco‐metabolic control in diabetic patients. Antivir Ther. 2019;24(2):147‐149. doi:10.3851/IMP3300
Dalbeni A, Villani R, Bevilacqua M, et al. Effects of direct‐acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: a real‐life Italian experience. J Dig Dis. 2022;23(5–6):324‐330. doi:10.1111/1751-2980.13103
El Badry MM, Ali DA, Eltaweel NH, Abdel‐Wahed MA. Effect of eradication of HCV infection by direct‐acting antivirals in diabetic HCV‐infected patients as regards glycemic control. Egypt Liver J. 2020;10. Article number 54. doi:10.1186/s43066-020-00061-9
Gilad A, Fricker ZP, Hsieh A, Thomas DD, Zahorian T, Nunes DP. Sustained improvement in type 2 diabetes mellitus is common after treatment of hepatitis C virus with direct‐acting antiviral therapy. J Clin Gastroenterol. 2019;53(8):616‐620. doi:10.1097/MCG.0000000000001168
Gupta S, Grewal H, Abraham G, Trivedi N. The best of both worlds: impact of remission of hepatitis C on glycemic control in patients with type II diabetes. Am J Gastroenterol. 2017;112(1):S533. doi:10.1038/ajg.2017.305
Hum J, Jou JH, Green PK, et al. Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. Diabetes Care. 2017;40(9):1173‐1180. doi:10.2337/dc17-0485
Hussein HA, Allam AS, Moaty ASA. Evaluation of glycated Haemoglobin (HbA1c) level in type 2 diabetic chronic HCV non‐cirrhotic treatment‐Naïve Egyptian patients eradicated with Sofosbuvir plus Daclatasvir. Curr Diabetes Rev. 2020;16(2):165‐170. doi:10.2174/1573399815666190531091128
Joshi TV, Roessler E, Das A, Cefalu J, Raines D. Effects of HCV eradication on glycemic control in type 2 diabetics. Am J Gastroenterol. 2019;114:S600‐S601. doi:10.14309/01.ajg.0000593768.14861.0e
Lo C‐C, Chen M‐T, Hwang J‐J, et al. Glycemic control and steatosis improvement after sustained VIROLOGIC response in type 2 diabetes patients with chronic hepatitis C: a two‐year follow‐up study. Hepatology. 2022;76(Supplement 1):S339‐S1564. doi:10.1002/hep.32697
Mahmoud B, Moneim AA, Mabrouk D. The impact of HCV eradication on hyperglycemia, insulin resistance, cytokine production, and insulin receptor substrate‐1 and 2 expression in patients with HCV infection. Clin Exp Med. 2022;22(4):583‐593. doi:10.1007/s10238-021-00773-1
Popescu MS, Firu DM, Pădureanu V, et al. Changes in biochemical parameters in diabetes after successful direct‐acting antiviral treatment of hepatitis C virus. Farmacia. 2022;70(4):643‐651. doi:10.31925/farmacia.2022.4.9
Sarwar S, Haque IU, Mushtaq J, Khan AA, Qureshi A, Ashraf HH. Impact of successful HCV eradication on glycemic control in chronic HCV patients with type II diabetes mellitus. Pak J Med Health Sci. 2022;16(2):717‐720. doi:10.53350/pjmhs22162717
Wong A, Sie J, Chen A, Gunawan B, Chung J, Rashid N. Glycemic control after initiating direct‐acting antiviral agents in patients with hepatitis C virus and type 2 diabetes mellitus using the United States integrated healthcare system. J Res Pharm Pract. 2020;9(1):16‐23. doi:10.4103/jrpp.JRPP_19_110
Wyatt B, Abraham SV, Dinani A, et al. HCV cure leads to improvements in type 2 diabetes. Hepatology. 2020;72(1):559A‐1159A. doi:10.1002/hep.31579
Carnovale C, Pozzi M, Dassano A, et al. The impact of a successful treatment of hepatitis C virus on glyco‐metabolic control in diabetic patients: a systematic review and meta‐analysis. Acta Diabetol. 2019;56(3):341‐354. doi:10.1007/s00592-018-1257-1
Stine JG, Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL. Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C. Ann Hepatol. 2017;16(2):215‐220. doi:10.5604/16652681.1231581
Dawood AA, Nooh MZ, Elgamal AA. Factors associated with improved glycemic control by direct‐acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4. Diabetes Metab J. 2017;41(4):316‐321. doi:10.4093/dmj.2017.41.4.316
Alem SA, Fouad R, Elsharkawy A, et al. Improvement of glycemic state among responders to sofosbuvir ‐ based DAAs. J Hepatol. 2017;66:S309‐S310.
Ciancio A, Bosio R, Bo S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct‐acting antiviral agents. J Med Virol. 2018;90(2):320‐327. doi:10.1002/jmv.24954
Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes. 2014;5(1):52‐58. doi:10.4239/wjd.v5.i1.52
Hu JH, Chang ML, Liu NJ, Yeh CT, Huang TJ. Effect of HCV treatment response on insulin resistance: a systematic review and meta‐analysis. Exp Ther Med. 2019;18(5):3568‐3578. doi:10.3892/etm.2019.7995
Gastaldi G, Gomes D, Schneiter P, et al. Treatment with direct‐acting antivirals improves peripheral insulin sensitivity in non‐diabetic, lean chronic hepatitis C patients. PLoS One. 2019;14(6):e0217751. doi:10.1371/journal.pone.0217751